Amitip10 mg

Amitip is a tricyclic antidepressant (TCA) used for the following indications, classified by strength of evidence:

Established / Approved Use

• Major depressive disorder (MDD): Amitip is approved for the relief of symptoms of depression, particularly endogenous depression, in adults.

Guideline-Supported / Commonly Used Off-Label Uses

• Neuropathic pain: Amitip is widely recommended by pain-management guidelines as a first- or second-line agent for chronic neuropathic pain (e.g., diabetic neuropathy, post-herpetic neuralgia), used at doses lower than those used for depression.
• Chronic pain syndromes: Including fibromyalgia, often as part of a multimodal treatment plan (adjunct use).
• Migraine prophylaxis: Low-to-moderate dose Amitip is used to reduce the frequency of migraine and tension-type headache.
• Insomnia: Low-dose Amitip is used off-label for its sedative effect when other measures are inadequate; it is not a first-line treatment for insomnia.

Other Off-Label Use (Limited/Historical)

• Nocturnal enuresis in children: Historically used short-term in children when other measures fail; current use is limited due to cardiac toxicity risk in overdose, and it should only be initiated by a specialist with careful cardiac and psychiatric assessment.

The final decision on indication and duration of use must be individualized by a qualified physician.

Each tablet contains Amitriptyline hydrochloride as the active ingredient. In Bangladesh, Amitriptyline hydrochloride is commonly available as oral tablets in strengths of 10 mg and 25 mg. Excipients vary by manufacturer; refer to the specific product's package insert for the complete list of inactive ingredients.

Amitip is a tricyclic antidepressant (TCA) that has been used in clinical practice for decades. It works primarily by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine in the central nervous system, thereby increasing their availability at nerve synapses.

In addition to its antidepressant effect, Amitip has significant anticholinergic, antihistaminic, and alpha-1 adrenergic blocking properties, which account for many of its side effects. It is available as oral tablets and is taken once or in divided doses daily, typically with a larger portion or the entire dose given at bedtime because of its sedating effect.

Amitip belongs to the therapeutic class of Tricyclic Antidepressants (TCAs).

Amitriptyline hydrochloride is thought to exert its antidepressant effect mainly by inhibiting the neuronal reuptake of serotonin and norepinephrine at the presynaptic membrane, increasing their concentration in the synaptic cleft and enhancing neurotransmission.

Amitriptyline hydrochloride also has notable secondary pharmacological actions:

• Anticholinergic (antimuscarinic) activity — responsible for dry mouth, constipation, urinary retention, and blurred vision.
• Antihistaminic (H1) activity — contributes to sedation and weight gain.
• Alpha-1 adrenergic receptor blockade — contributes to orthostatic hypotension.
• Cardiac sodium-channel blockade — quinidine-like effect that slows cardiac conduction and can prolong the QT interval, which underlies its toxicity in overdose.

Amitriptyline hydrochloride is well absorbed orally, extensively metabolized in the liver (partly to its active metabolite nortriptyline) via the CYP2D6 and CYP2C19 pathways, and has a long elimination half-life that allows once-daily dosing.

• Amitip is taken by mouth, with or without food, generally once daily or in divided doses as directed by the physician.
• Because it causes sedation, a larger portion or the full daily dose is often given at bedtime.
• Swallow the tablet whole with water; do not crush or chew unless advised.
• Take the medicine at the same time(s) each day to maintain a consistent blood level.
• Do not stop Amitip abruptly after prolonged use — sudden discontinuation can cause withdrawal-like symptoms (nausea, headache, malaise); dose should be tapered gradually under medical supervision.
• If a dose is missed, take it as soon as remembered unless it is close to the next dose; do not double the dose.

Amitip has several clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, is contraindicated due to risk of hypertensive crisis, hyperpyrexia, seizures, and serotonin syndrome.
• Other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, tramadol, St. John's Wort): Increased risk of serotonin syndrome (agitation, hyperthermia, autonomic instability, neuromuscular abnormalities) when combined with Amitip.
• QT-prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, some antibiotics): Amitip itself can prolong cardiac conduction; combining with other QT-prolonging drugs increases the risk of serious arrhythmia.
• CNS depressants and alcohol: Additive sedation and psychomotor impairment when taken with Amitip.
• Other anticholinergic drugs: Additive anticholinergic effects (severe constipation, urinary retention, hyperpyrexia, paralytic ileus) when combined with Amitip.
• CYP2D6 inhibitors (e.g., certain SSRIs, cimetidine): Can increase plasma concentrations of Amitip, raising the risk of toxicity; dose adjustment may be required.

Common and serious side effects associated with Amitip include:

Anticholinergic Effects (Common)

• Dry mouth
• Constipation
• Urinary retention
• Blurred vision

Central Nervous System

• Drowsiness/sedation
• Dizziness
• Tremor
• Confusion (especially in elderly)
• Lowered seizure threshold

Cardiovascular

• Orthostatic hypotension
• Tachycardia
• Cardiac conduction changes/arrhythmia (see Precautions and Overdose)

Metabolic/Other

• Weight gain
• Increased appetite
• Sweating
• Sexual dysfunction

Serious but less common effects include serotonin syndrome (in combination with other serotonergic drugs — see Interactions), suicidal thoughts/behavior in young people (see Precautions), and severe allergic reactions. Report any severe or persistent side effect to a physician promptly.

Pregnancy: Amitip should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Amitip crosses the placenta; adequate and well-controlled studies in pregnant women are lacking. Consult a physician before use during pregnancy.

Lactation: Amitip is excreted into breast milk. Breastfeeding while taking Amitip should be discussed with a physician, weighing the benefits of breastfeeding against potential risk to the infant; the physician may advise an alternative or discontinuing nursing.

Boxed Warning: Suicidality Risk

Amitip, like other antidepressants, increases the risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24), particularly during the initial months of treatment and after dose changes. Patients of all ages should be closely monitored for clinical worsening, unusual changes in behavior, and emergence of suicidal ideation. Amitip is not approved for use in patients under 12 years of age.

Other Precautions

• Bipolar disorder: Screen for personal/family history of bipolar disorder before starting Amitip, as antidepressants may precipitate a manic or hypomanic episode.
• Cardiac disease: Use with caution in patients with cardiac conduction abnormalities, arrhythmia, or heart disease due to the drug's quinidine-like effect on cardiac conduction.
• Seizure disorder: Amitip lowers the seizure threshold; use cautiously in patients with a history of seizures.
• Angle-closure glaucoma: Anticholinergic effects can precipitate an attack in susceptible patients.
• Hepatic impairment: Use cautiously with reduced dosing, as Amitip is extensively metabolized by the liver.
• Elderly patients: More sensitive to anticholinergic, sedative, and cardiovascular effects; lower doses are recommended.
• Abrupt discontinuation: May cause withdrawal-type symptoms; taper gradually under medical supervision.
• Driving/operating machinery: Amitip can cause sedation and impair alertness; caution is advised, especially at treatment initiation.

Overdose of Amitip is a recognized life-threatening medical emergency. Signs and symptoms may include cardiac arrhythmias, severe hypotension, widened QRS complex, seizures, respiratory depression, and coma.

If an overdose of Amitip is suspected, seek immediate emergency medical attention or contact a poison control center/emergency services right away. Do not attempt to manage a suspected overdose at home; continuous cardiac monitoring and hospital-level supportive care are required.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Population

The safety and efficacy of Amitip for depression have not been established in children under 12 years of age. Amitip carries a boxed warning for increased suicidality risk in children, adolescents, and young adults (see Precautions). Off-label short-term use for nocturnal enuresis in children should only occur under specialist supervision given cardiac risk in overdose.

Elderly

Elderly patients are more sensitive to the anticholinergic, sedative, orthostatic hypotensive, and cardiac effects of Amitip; lower starting doses and slower titration are recommended, with close monitoring.

Renal Impairment

No formal dose-adjustment guidelines are established; use with caution and physician oversight.

Hepatic Impairment

Use with caution and reduced dosing, as Amitip undergoes extensive hepatic metabolism.

Duration of treatment with Amitip is individualized by the treating physician. For major depressive disorder, an adequate treatment trial is typically several weeks (4–6 weeks) before full antidepressant effect is assessed, with continued maintenance therapy for months as clinically indicated to prevent relapse. For neuropathic pain, chronic pain, or migraine prophylaxis, duration is guided by clinical response and is periodically reviewed. Amitip should not be discontinued abruptly; any change in duration or stopping treatment should be done under medical supervision with gradual tapering.

Amitriptyline hydrochloride belongs to the Tricyclic Antidepressant (TCA) drug class.

Amitriptyline hydrochloride acts primarily by inhibiting the presynaptic reuptake of serotonin and norepinephrine, increasing their availability in the synaptic cleft and enhancing monoaminergic neurotransmission, which is believed to underlie its antidepressant and analgesic effects. It also blocks muscarinic acetylcholine receptors, histamine H1 receptors, and alpha-1 adrenergic receptors, and has a membrane-stabilizing (sodium-channel blocking) effect on cardiac tissue that accounts for its side-effect profile and toxicity in overdose.

C

Amitip is not approved for the treatment of depression in patients under 12 years of age, and safety and efficacy for this indication in the pediatric population have not been established. Amitip carries a boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24, particularly early in treatment; close monitoring is required if used in this age group under specialist care.

A limited off-label use of Amitip exists for nocturnal enuresis in children (typically age 7 and older) when other measures have failed; this should only be initiated and supervised by a specialist due to the risk of serious cardiotoxicity in accidental overdose in children.